Invitae Corporation
Invitae Corporation NVTA Peers
See (NVTA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVTA | $0.02 | -35.59% | 5.4M | -0.00 | -$5.36 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.70% |
| TMO | $434.67 | +3.52% | 162.7B | 25.26 | $17.06 | +0.47% |
| DHR | $204.75 | +1.89% | 147.1B | 39.83 | $5.16 | +0.70% |
| IDXX | $532.07 | -1.59% | 43.5B | 50.04 | $10.81 | N/A |
| A | $122.93 | +1.34% | 35.3B | 30.65 | $4.05 | +0.98% |
| IQV | $162.44 | +0.26% | 28.6B | 22.59 | $7.33 | N/A |
| MTD | $1,221.70 | +0.25% | 25.7B | 30.90 | $40.06 | N/A |
| NTRA | $162.02 | +0.17% | 22.3B | -111.17 | -$1.47 | N/A |
| WAT | $353.28 | +1.17% | 21B | 32.03 | $11.03 | N/A |
Stock Comparison
NVTA vs DHR-PB Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, NVTA is priced at $0.02, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, NVTA is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs TMO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TMO has a market cap of 162.7B. Regarding current trading prices, NVTA is priced at $0.02, while TMO trades at $434.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TMO's P/E ratio is 25.26. In terms of profitability, NVTA's ROE is -2.02%, compared to TMO's ROE of +0.13%. Regarding short-term risk, NVTA is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs DHR Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, NVTA is priced at $0.02, while DHR trades at $204.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR's P/E ratio is 39.83. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR's ROE of +0.07%. Regarding short-term risk, NVTA is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs IDXX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, IDXX has a market cap of 43.5B. Regarding current trading prices, NVTA is priced at $0.02, while IDXX trades at $532.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas IDXX's P/E ratio is 50.04. In terms of profitability, NVTA's ROE is -2.02%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, NVTA is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs A Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, A has a market cap of 35.3B. Regarding current trading prices, NVTA is priced at $0.02, while A trades at $122.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas A's P/E ratio is 30.65. In terms of profitability, NVTA's ROE is -2.02%, compared to A's ROE of +0.19%. Regarding short-term risk, NVTA is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs IQV Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, IQV has a market cap of 28.6B. Regarding current trading prices, NVTA is priced at $0.02, while IQV trades at $162.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas IQV's P/E ratio is 22.59. In terms of profitability, NVTA's ROE is -2.02%, compared to IQV's ROE of +0.21%. Regarding short-term risk, NVTA is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MTD Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MTD has a market cap of 25.7B. Regarding current trading prices, NVTA is priced at $0.02, while MTD trades at $1,221.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MTD's P/E ratio is 30.90. In terms of profitability, NVTA's ROE is -2.02%, compared to MTD's ROE of +1.21%. Regarding short-term risk, NVTA is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs NTRA Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NTRA has a market cap of 22.3B. Regarding current trading prices, NVTA is priced at $0.02, while NTRA trades at $162.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NTRA's P/E ratio is -111.17. In terms of profitability, NVTA's ROE is -2.02%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, NVTA is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs WAT Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, WAT has a market cap of 21B. Regarding current trading prices, NVTA is priced at $0.02, while WAT trades at $353.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas WAT's P/E ratio is 32.03. In terms of profitability, NVTA's ROE is -2.02%, compared to WAT's ROE of +0.39%. Regarding short-term risk, NVTA is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs DGX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DGX has a market cap of 19.1B. Regarding current trading prices, NVTA is priced at $0.02, while DGX trades at $168.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DGX's P/E ratio is 21.68. In terms of profitability, NVTA's ROE is -2.02%, compared to DGX's ROE of +0.13%. Regarding short-term risk, NVTA is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ILMN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ILMN has a market cap of 15.8B. Regarding current trading prices, NVTA is priced at $0.02, while ILMN trades at $99.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ILMN's P/E ratio is -16.46. In terms of profitability, NVTA's ROE is -2.02%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, NVTA is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PKI Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, NVTA is priced at $0.02, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PKI's P/E ratio is 41.45. In terms of profitability, NVTA's ROE is -2.02%, compared to PKI's ROE of +0.04%. Regarding short-term risk, NVTA is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ICLR Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ICLR has a market cap of 12.3B. Regarding current trading prices, NVTA is priced at $0.02, while ICLR trades at $150.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ICLR's P/E ratio is 16.58. In terms of profitability, NVTA's ROE is -2.02%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs RVTY Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, RVTY has a market cap of 12.1B. Regarding current trading prices, NVTA is priced at $0.02, while RVTY trades at $101.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas RVTY's P/E ratio is 42.32. In terms of profitability, NVTA's ROE is -2.02%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, NVTA is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs QGEN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, QGEN has a market cap of 10.5B. Regarding current trading prices, NVTA is priced at $0.02, while QGEN trades at $47.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas QGEN's P/E ratio is 112.84. In terms of profitability, NVTA's ROE is -2.02%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, NVTA is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs EXAS Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, EXAS has a market cap of 10.1B. Regarding current trading prices, NVTA is priced at $0.02, while EXAS trades at $52.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas EXAS's P/E ratio is -9.65. In terms of profitability, NVTA's ROE is -2.02%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, NVTA is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs TEM Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TEM has a market cap of 10B. Regarding current trading prices, NVTA is priced at $0.02, while TEM trades at $57.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TEM's P/E ratio is -11.55. In terms of profitability, NVTA's ROE is -2.02%, compared to TEM's ROE of -5.31%. Regarding short-term risk, NVTA is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MEDP Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MEDP has a market cap of 9.4B. Regarding current trading prices, NVTA is priced at $0.02, while MEDP trades at $322.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MEDP's P/E ratio is 25.07. In terms of profitability, NVTA's ROE is -2.02%, compared to MEDP's ROE of +0.54%. Regarding short-term risk, NVTA is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CRL Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CRL has a market cap of 8B. Regarding current trading prices, NVTA is priced at $0.02, while CRL trades at $159.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CRL's P/E ratio is -263.97. In terms of profitability, NVTA's ROE is -2.02%, compared to CRL's ROE of -0.01%. Regarding short-term risk, NVTA is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs GH Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GH has a market cap of 6.4B. Regarding current trading prices, NVTA is priced at $0.02, while GH trades at $50.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GH's P/E ratio is -15.13. In terms of profitability, NVTA's ROE is -2.02%, compared to GH's ROE of +3.69%. Regarding short-term risk, NVTA is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs SYNH Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, NVTA is priced at $0.02, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SYNH's P/E ratio is 61.40. In terms of profitability, NVTA's ROE is -2.02%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, NVTA is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs RDNT Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, RDNT has a market cap of 4.3B. Regarding current trading prices, NVTA is priced at $0.02, while RDNT trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas RDNT's P/E ratio is -133.77. In terms of profitability, NVTA's ROE is -2.02%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, NVTA is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs SHC Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SHC has a market cap of 3.4B. Regarding current trading prices, NVTA is priced at $0.02, while SHC trades at $11.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SHC's P/E ratio is 132.06. In terms of profitability, NVTA's ROE is -2.02%, compared to SHC's ROE of +0.06%. Regarding short-term risk, NVTA is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs OLK Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, NVTA is priced at $0.02, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OLK's P/E ratio is -96.59. In terms of profitability, NVTA's ROE is -2.02%, compared to OLK's ROE of -0.07%. Regarding short-term risk, NVTA is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs TWST Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TWST has a market cap of 2.3B. Regarding current trading prices, NVTA is priced at $0.02, while TWST trades at $37.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TWST's P/E ratio is -11.84. In terms of profitability, NVTA's ROE is -2.02%, compared to TWST's ROE of -0.41%. Regarding short-term risk, NVTA is more volatile compared to TWST. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs GRAL Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GRAL has a market cap of 1.6B. Regarding current trading prices, NVTA is priced at $0.02, while GRAL trades at $41.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GRAL's P/E ratio is -0.73. In terms of profitability, NVTA's ROE is -2.02%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, NVTA is more volatile compared to GRAL. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs VIVO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, NVTA is priced at $0.02, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas VIVO's P/E ratio is 21.09. In terms of profitability, NVTA's ROE is -2.02%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, NVTA is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs NEOG Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NEOG has a market cap of 1.2B. Regarding current trading prices, NVTA is priced at $0.02, while NEOG trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NEOG's P/E ratio is -2.51. In terms of profitability, NVTA's ROE is -2.02%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, NVTA is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CDNA Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CDNA has a market cap of 1.1B. Regarding current trading prices, NVTA is priced at $0.02, while CDNA trades at $20.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CDNA's P/E ratio is 18.44. In terms of profitability, NVTA's ROE is -2.02%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, NVTA is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs OPK Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, NVTA is priced at $0.02, while OPK trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OPK's P/E ratio is -22.58. In terms of profitability, NVTA's ROE is -2.02%, compared to OPK's ROE of -0.03%. Regarding short-term risk, NVTA is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PSNL Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PSNL has a market cap of 610.8M. Regarding current trading prices, NVTA is priced at $0.02, while PSNL trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PSNL's P/E ratio is -5.36. In terms of profitability, NVTA's ROE is -2.02%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, NVTA is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs FLGT Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, FLGT has a market cap of 594.9M. Regarding current trading prices, NVTA is priced at $0.02, while FLGT trades at $19.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas FLGT's P/E ratio is -14.69. In terms of profitability, NVTA's ROE is -2.02%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, NVTA is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs GRALV Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, NVTA is priced at $0.02, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GRALV's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to GRALV's ROE of N/A. Regarding short-term risk, NVTA is more volatile compared to GRALV. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CSTL Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CSTL has a market cap of 573.1M. Regarding current trading prices, NVTA is priced at $0.02, while CSTL trades at $19.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CSTL's P/E ratio is -104.47. In terms of profitability, NVTA's ROE is -2.02%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, NVTA is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs LAB Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LAB has a market cap of 509M. Regarding current trading prices, NVTA is priced at $0.02, while LAB trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LAB's P/E ratio is -4.19. In terms of profitability, NVTA's ROE is -2.02%, compared to LAB's ROE of -0.28%. Regarding short-term risk, NVTA is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MYGN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MYGN has a market cap of 506.5M. Regarding current trading prices, NVTA is priced at $0.02, while MYGN trades at $5.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MYGN's P/E ratio is -4.91. In terms of profitability, NVTA's ROE is -2.02%, compared to MYGN's ROE of -0.14%. Regarding short-term risk, NVTA is more volatile compared to MYGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, NVTA is priced at $0.02, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CO's P/E ratio is 5.06. In terms of profitability, NVTA's ROE is -2.02%, compared to CO's ROE of +0.11%. Regarding short-term risk, NVTA is more volatile compared to CO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs FLDM Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, NVTA is priced at $0.02, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas FLDM's P/E ratio is -4.74. In terms of profitability, NVTA's ROE is -2.02%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, NVTA is more volatile compared to FLDM. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs STIM Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, STIM has a market cap of 233.3M. Regarding current trading prices, NVTA is priced at $0.02, while STIM trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas STIM's P/E ratio is -2.69. In terms of profitability, NVTA's ROE is -2.02%, compared to STIM's ROE of -2.09%. Regarding short-term risk, NVTA is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs NEO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NEO has a market cap of 192.7M. Regarding current trading prices, NVTA is priced at $0.02, while NEO trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NEO's P/E ratio is -12.27. In terms of profitability, NVTA's ROE is -2.02%, compared to NEO's ROE of -0.09%. Regarding short-term risk, NVTA is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ACRS Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ACRS has a market cap of 171.6M. Regarding current trading prices, NVTA is priced at $0.02, while ACRS trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ACRS's P/E ratio is -1.00. In terms of profitability, NVTA's ROE is -2.02%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, NVTA is more volatile compared to ACRS. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs XGN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, XGN has a market cap of 152.4M. Regarding current trading prices, NVTA is priced at $0.02, while XGN trades at $6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas XGN's P/E ratio is -8.30. In terms of profitability, NVTA's ROE is -2.02%, compared to XGN's ROE of -1.34%. Regarding short-term risk, NVTA is more volatile compared to XGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ATLN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ATLN has a market cap of 136.2M. Regarding current trading prices, NVTA is priced at $0.02, while ATLN trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ATLN's P/E ratio is -0.60. In terms of profitability, NVTA's ROE is -2.02%, compared to ATLN's ROE of -42.96%. Regarding short-term risk, NVTA is more volatile compared to ATLN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs GTH Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, NVTA is priced at $0.02, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GTH's P/E ratio is -1.11. In terms of profitability, NVTA's ROE is -2.02%, compared to GTH's ROE of -1.01%. Regarding short-term risk, NVTA is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs GENE Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, NVTA is priced at $0.02, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas GENE's P/E ratio is -38.25. In terms of profitability, NVTA's ROE is -2.02%, compared to GENE's ROE of -3.62%. Regarding short-term risk, NVTA is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MDXH Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MDXH has a market cap of 108.4M. Regarding current trading prices, NVTA is priced at $0.02, while MDXH trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MDXH's P/E ratio is -2.11. In terms of profitability, NVTA's ROE is -2.02%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, NVTA is more volatile compared to MDXH. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PRE Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRE has a market cap of 101.7M. Regarding current trading prices, NVTA is priced at $0.02, while PRE trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRE's P/E ratio is -2.05. In terms of profitability, NVTA's ROE is -2.02%, compared to PRE's ROE of -0.28%. Regarding short-term risk, NVTA is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs SERA Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SERA has a market cap of 100.9M. Regarding current trading prices, NVTA is priced at $0.02, while SERA trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SERA's P/E ratio is -2.93. In terms of profitability, NVTA's ROE is -2.02%, compared to SERA's ROE of -0.51%. Regarding short-term risk, NVTA is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PRENW Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRENW has a market cap of 98.8M. Regarding current trading prices, NVTA is priced at $0.02, while PRENW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRENW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, NVTA is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs NOTV Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NOTV has a market cap of 72.3M. Regarding current trading prices, NVTA is priced at $0.02, while NOTV trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NOTV's P/E ratio is -0.67. In terms of profitability, NVTA's ROE is -2.02%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, NVTA is more volatile compared to NOTV. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs VNRX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, VNRX has a market cap of 70.1M. Regarding current trading prices, NVTA is priced at $0.02, while VNRX trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas VNRX's P/E ratio is -2.52. In terms of profitability, NVTA's ROE is -2.02%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, NVTA is more volatile compared to VNRX. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs OPGN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OPGN has a market cap of 45.8M. Regarding current trading prices, NVTA is priced at $0.02, while OPGN trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OPGN's P/E ratio is -0.29. In terms of profitability, NVTA's ROE is -2.02%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, NVTA is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BDSX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BDSX has a market cap of 45M. Regarding current trading prices, NVTA is priced at $0.02, while BDSX trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BDSX's P/E ratio is -1.14. In terms of profitability, NVTA's ROE is -2.02%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, NVTA is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs DRIO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DRIO has a market cap of 31.9M. Regarding current trading prices, NVTA is priced at $0.02, while DRIO trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DRIO's P/E ratio is -1.30. In terms of profitability, NVTA's ROE is -2.02%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, NVTA is more volatile compared to DRIO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs STRRP Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, STRRP has a market cap of 30.2M. Regarding current trading prices, NVTA is priced at $0.02, while STRRP trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas STRRP's P/E ratio is -4.71. In terms of profitability, NVTA's ROE is -2.02%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, NVTA is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs AKU Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, NVTA is priced at $0.02, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas AKU's P/E ratio is -0.13. In terms of profitability, NVTA's ROE is -2.02%, compared to AKU's ROE of -5.32%. Regarding short-term risk, NVTA is more volatile compared to AKU. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PRPO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PRPO has a market cap of 23.7M. Regarding current trading prices, NVTA is priced at $0.02, while PRPO trades at $15.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PRPO's P/E ratio is -7.62. In terms of profitability, NVTA's ROE is -2.02%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, NVTA is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ADVB Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ADVB has a market cap of 16.9M. Regarding current trading prices, NVTA is priced at $0.02, while ADVB trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ADVB's P/E ratio is -4.87. In terms of profitability, NVTA's ROE is -2.02%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, NVTA is more volatile compared to ADVB. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CEMI Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, NVTA is priced at $0.02, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CEMI's P/E ratio is -0.63. In terms of profitability, NVTA's ROE is -2.02%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, NVTA is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ENZ Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, NVTA is priced at $0.02, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ENZ's P/E ratio is -2.24. In terms of profitability, NVTA's ROE is -2.02%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, NVTA is more volatile compared to ENZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs PMD Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, NVTA is priced at $0.02, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas PMD's P/E ratio is -5.24. In terms of profitability, NVTA's ROE is -2.02%, compared to PMD's ROE of -0.33%. Regarding short-term risk, NVTA is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs TRIB Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TRIB has a market cap of 14.3M. Regarding current trading prices, NVTA is priced at $0.02, while TRIB trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TRIB's P/E ratio is -0.43. In terms of profitability, NVTA's ROE is -2.02%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, NVTA is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ME Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, NVTA is priced at $0.02, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ME's P/E ratio is -0.03. In terms of profitability, NVTA's ROE is -2.02%, compared to ME's ROE of -3.99%. Regarding short-term risk, NVTA is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs INBS Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, INBS has a market cap of 12.6M. Regarding current trading prices, NVTA is priced at $0.02, while INBS trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas INBS's P/E ratio is -1.37. In terms of profitability, NVTA's ROE is -2.02%, compared to INBS's ROE of -1.72%. Regarding short-term risk, NVTA is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BNGO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BNGO has a market cap of 11.4M. Regarding current trading prices, NVTA is priced at $0.02, while BNGO trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BNGO's P/E ratio is -0.06. In terms of profitability, NVTA's ROE is -2.02%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, NVTA is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BGLC Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BGLC has a market cap of 10.8M. Regarding current trading prices, NVTA is priced at $0.02, while BGLC trades at $5.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BGLC's P/E ratio is -5.04. In terms of profitability, NVTA's ROE is -2.02%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, NVTA is more volatile compared to BGLC. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CNTG Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CNTG has a market cap of 9.2M. Regarding current trading prices, NVTA is priced at $0.02, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CNTG's P/E ratio is -0.23. In terms of profitability, NVTA's ROE is -2.02%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, NVTA is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BIAF Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIAF has a market cap of 8.8M. Regarding current trading prices, NVTA is priced at $0.02, while BIAF trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIAF's P/E ratio is -0.43. In terms of profitability, NVTA's ROE is -2.02%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, NVTA is more volatile compared to BIAF. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MYNZ Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MYNZ has a market cap of 7.6M. Regarding current trading prices, NVTA is priced at $0.02, while MYNZ trades at $1.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MYNZ's P/E ratio is -0.09. In terms of profitability, NVTA's ROE is -2.02%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, NVTA is more volatile compared to MYNZ. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs STRR Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, STRR has a market cap of 6.2M. Regarding current trading prices, NVTA is priced at $0.02, while STRR trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas STRR's P/E ratio is -0.65. In terms of profitability, NVTA's ROE is -2.02%, compared to STRR's ROE of -0.24%. Regarding short-term risk, NVTA is more volatile compared to STRR. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BIAFW Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIAFW has a market cap of 6M. Regarding current trading prices, NVTA is priced at $0.02, while BIAFW trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIAFW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, NVTA is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs NDRA Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, NDRA has a market cap of 5.9M. Regarding current trading prices, NVTA is priced at $0.02, while NDRA trades at $8.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas NDRA's P/E ratio is 0.02. In terms of profitability, NVTA's ROE is -2.02%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, NVTA is more volatile compared to NDRA. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs LMDX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, NVTA is priced at $0.02, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LMDX's P/E ratio is -0.01. In terms of profitability, NVTA's ROE is -2.02%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, NVTA is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for NVTA.
NVTA vs LMDXW Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, NVTA is priced at $0.02, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, NVTA's ROE is -2.02%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, NVTA is more volatile compared to LMDXW. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs CHEK Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, CHEK has a market cap of 4.6M. Regarding current trading prices, NVTA is priced at $0.02, while CHEK trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas CHEK's P/E ratio is -0.37. In terms of profitability, NVTA's ROE is -2.02%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, NVTA is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BNR Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BNR has a market cap of 4.2M. Regarding current trading prices, NVTA is priced at $0.02, while BNR trades at $4.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BNR's P/E ratio is -1.23. In terms of profitability, NVTA's ROE is -2.02%, compared to BNR's ROE of -0.39%. Regarding short-term risk, NVTA is more volatile compared to BNR. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs TTOO Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, TTOO has a market cap of 3.5M. Regarding current trading prices, NVTA is priced at $0.02, while TTOO trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas TTOO's P/E ratio is -4.17. In terms of profitability, NVTA's ROE is -2.02%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, NVTA is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs DMTK Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, NVTA is priced at $0.02, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DMTK's P/E ratio is -0.04. In terms of profitability, NVTA's ROE is -2.02%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, NVTA is more volatile compared to DMTK. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs AWH Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, NVTA is priced at $0.02, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas AWH's P/E ratio is -0.09. In terms of profitability, NVTA's ROE is -2.02%, compared to AWH's ROE of +4.66%. Regarding short-term risk, NVTA is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs APDN Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, APDN has a market cap of 2.8M. Regarding current trading prices, NVTA is priced at $0.02, while APDN trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas APDN's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to APDN's ROE of -2.81%. Regarding short-term risk, NVTA is more volatile compared to APDN. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs ISPC Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, ISPC has a market cap of 2.7M. Regarding current trading prices, NVTA is priced at $0.02, while ISPC trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas ISPC's P/E ratio is -0.09. In terms of profitability, NVTA's ROE is -2.02%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, NVTA is more volatile compared to ISPC. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs SQL Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, NVTA is priced at $0.02, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SQL's P/E ratio is -0.40. In terms of profitability, NVTA's ROE is -2.02%, compared to SQL's ROE of +10.89%. Regarding short-term risk, NVTA is more volatile compared to SQL. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs HTGM Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, NVTA is priced at $0.02, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas HTGM's P/E ratio is -0.03. In terms of profitability, NVTA's ROE is -2.02%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, NVTA is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs BIOC Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, NVTA is priced at $0.02, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas BIOC's P/E ratio is -0.01. In terms of profitability, NVTA's ROE is -2.02%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, NVTA is more volatile compared to BIOC. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs SQLLW Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, NVTA is priced at $0.02, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, NVTA's ROE is -2.02%, compared to SQLLW's ROE of -42.96%. Regarding short-term risk, NVTA is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs OCDX Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas OCDX's P/E ratio is -42.28. In terms of profitability, NVTA's ROE is -2.02%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, NVTA is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs DHR-PA Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, NVTA's ROE is -2.02%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, NVTA is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.
NVTA vs MEUSW Comparison
NVTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVTA stands at 5.4M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, NVTA is priced at $0.02, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVTA currently has a P/E ratio of -0.00, whereas MEUSW's P/E ratio is N/A. In terms of profitability, NVTA's ROE is -2.02%, compared to MEUSW's ROE of -3.99%. Regarding short-term risk, NVTA is more volatile compared to MEUSW. This indicates potentially higher risk in terms of short-term price fluctuations for NVTA.